Laparoscopic Sleeve Gastrectomy In The Management Of Metabolic Syndrome. Our Experience

Introduction: The rapid reversal of diabetes, hypertension, hyperlipidemia and morbid obesity (MO) by bariatric surgery has challenged the management of metabolic syndrome. Laparoscopic sleeve gastrectomy (LSG), which developed initially as a first-step procedure for biliopancreatic diversion with duodenal switch, has seen an exponential rise in popularity as an effective alone laparoscopic bariatric procedure. Material and method: We encountered 268 pts. with LSG performed between 2010 and 2014. We study 134 pts. with metabolic syndrome, with a median follow-up period of 18 months (range 12-52 months). We prospectively collected data regarding excess weight loss (EWL), blood pressure, diabetes mellitus (DM)), hormonal status and lipidic profile of the patients. Results: Diabetus mellitus remission after sleeve gastrectomy - 87.67%, hypertension remission is 63.82 %, The most significant value was for sleeve gastrectomy - 74.45 % after 1 year, EWL was 74.45 % after 1 year. Conclusions: Superior excess weight loss, a low complication rate, and excellent food tolerance, combined with a short hospital stay, have made this the procedure of choice for patients and surgeons across the globe. Optimum surgical outcomes allow minimization of metabolic syndrome, reducing cardiovascular and cerebrovascular risk.